



National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study

Giuseppe Vittorio De Socio¹ · Anna Gidari¹ · Francesco Sicari² · Michele Palumbo² · Daniela Francisci¹

Received: 27 June 2020 / Accepted: 27 April 2021 / Published online: 10 May 2021
© The Author(s) 2021

Abstract

Purpose Clinical scores to rapidly assess the severity illness of Coronavirus Disease 2019 (COVID-19) could be considered of help for clinicians. Recently, a specific score (named COVID-GRAM) for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, based on a nationwide Chinese cohort, has been proposed. We routinely applied the National Early Warning Score 2 (NEWS2) to predict critical COVID-19. Aim of this study is to compare NEWS2 and COVID-GRAM score.

Methods We retrospectively analysed data of 121 COVID-19 patients admitted in two Clinics of Infectious Diseases in the Umbria region, Italy. The primary outcome was critical COVID-19 illness defined as admission to the intensive care unit, invasive ventilation, or death. Accuracy of the scores was evaluated with the area under the receiver-operating characteristic curve (AUROC). Differences between scores were confirmed used Hanley–McNeil test.

Results The NEWS2 AUROC curve measured 0.87 (standard error, SE 0.03; 95% CI 0.80–0.93; $p < 0.0001$). The COVID-GRAM score AUROC curve measured 0.77 (SE 0.04; 95% CI 0.68–0.85; $p < 0.0001$). Hanley–McNeil test showed that NEWS2 better predicted severe COVID-19 ($Z = 2.03$).

Conclusions The NEWS2 showed superior accuracy to COVID-GRAM score for prediction of critical COVID-19 illness.

Keywords COVID-19 · SARS-CoV-2 · NEWS2 · National Early Warning Score 2 · COVID-GRAM

Introduction

A new Coronavirus, subsequently named severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) widely spread on Wuhan City, Hubei province, since December 2019, causing a diffusive type of interstitial pneumonia. In the following months, it diffused all over the world, becoming a global issue and forcing the World Health Organization to declare Coronavirus Disease 2019 (COVID-19) as a pandemic in March 2020.

An early assessment of illness severity for stratification of patients with SARS-CoV-2 infection is a relevant clinical need. Recently, Liang et al. [1] developed an interesting, specific score risk for COVID-19 that may help predict critical illness (COVID-GRAM). Briefly, authors, analysing a wide Chinese nationwide cohort, through a least absolute shrinkage and selection operator (LASSO) and logistic regression, constructed a predictive risk score (COVID-GRAM).

During this emergency period, in our clinical practice, we evaluated the predictive value of national early warning score 2 (NEWS2) to identify high-risk patients for intensive

✉ Anna Gidari
anna.gidari@studenti.unipg.it

Giuseppe Vittorio De Socio
giuseppedesocio@yahoo.it

Francesco Sicari
cicciosicari.com@hotmail.it

Michele Palumbo
m.palumbo@aospn.terni.it

Daniela Francisci
daniela.francisci@unipg.it

¹ Department of Medicine and Surgery, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, Università degli Studi di Perugia, Piazzale Lucio Severi 1, 06132 Perugia, Italy

² Department of Medicine, Clinic of Infectious Diseases, “Santa Maria” Hospital, 05100 Terni, Italy

care unit (ICU) admission [2]. The NEWS2 was primarily validated for death and intensive care need in septic patients. It is a modified version of NEWS, which is commonly used in British hospitals for identification of patients with a high risk of deterioration [3].

This study aimed to compare the diagnostic accuracy of COVID-GRAM score proposed by Liang et al. and NEWS2 for predicting critical COVID-19 illness in a cohort of patients hospitalised for SARS-CoV-2 in Umbria region.

Methods

This study is a retrospective, multi-centre accuracy study. Consecutive adult COVID-19 patients admitted to the Clinic of Infectious Diseases of Perugia Hospital, Umbria region, Italy, and Clinic of Infectious Diseases of Terni Hospital, Umbria region, Italy, from March 01, 2020 to June 15, 2020, were recruited. All subjects provided informed oral consent to clinical data collection. Data were collected using the same database in both centres to guarantee the homogeneity of the cohort.

All adult patients (age ≥ 18 years old) with an established diagnosis of SARS-CoV-2 infection were included. [4] The infection was established for patients with at least a sample (nasopharyngeal swab, bronchoalveolar lavage, and sputum) positive for the SARS-CoV-2 (molecular diagnosis with real-time polymerase chain reaction, PCR). The study was approved by the Ethics Committee of the Umbria Region (protocol number 18344/20/OV).

Data on demographics, comorbidities and clinical presentation were obtained for each patient. COVID-GRAM and NEWS2 at hospital admission were calculated using medical records.

Exclusion criteria were missing information that did not permit to calculate NEWS2 or COVID-GRAM. The primary outcome was critical COVID-19 illness as defined by Liang et al. [1]: admission to the ICU, invasive ventilation, or death.

Data were summarised as mean with the respective standard deviation (SD) or median with the respective interquartile range (IQR).

Differences between groups were determined using the Mann–Whitney test, the Student's *t* test, or the X^2 as appropriate.

NEWS2 is based on aggregate scoring of the following parameters: respiratory rate, hypercapnic respiratory failure, supplemental oxygen, body temperature, systolic blood pressure, pulse rate and level of consciousness. The combination of these values provides a score between 0 and 20 [3].

COVID-GRAM is a composite score calculated using the following formula: COVID-GRAM risk score = (X-ray abnormality $\times 27.1464$) + (age $\times 0.6139$) + (hemop-

tysis $\times 33.6210$) + (dyspnoea $\times 14.0569$) + (unconsciousness $\times 34.4617$) + (number of comorbidities $\times 10.3826$) + (cancer history $\times 31.2211$) + (neutrophil/lymphocyte ratio, N/L $\times 1.25$) + (lactate dehydrogenase, LDH $\times 0.0534$) + (direct bilirubin $\times 3.0605$). Age, number of comorbidities, N/L, LDH and direct bilirubin are continuous variables, and the others are categorical variables (expressed with 1 if positive and 0 if negative) [1].

Performances of NEWS2 and COVID-GRAM were evaluated by receiver-operating characteristic (ROC) curve analysis, describing areas under curves (AUROC) with their 95% confidence interval (CI) and comparing them to the null hypothesis (area = 0.5) [5–7]. The probability value (*p*) of the ROC curve was assessed using the Mann–Whitney *U* test. The Hanley–McNeil test was performed to establish if differences between ROC curves area were significant: areas under the ROC curve with critical *Z* ratio ≥ 1.96 were considered different [7].


For each score, the optimal threshold was chosen basing on the Youden index [8]. In addition, the performance of the score at the optimal threshold was assessed by the corresponding sensitivity and specificity, positive and negative likelihood ratio, positive and negative predictive value, and accuracy. Each value is reported with 95% confidence intervals (CI).

In clinical practice, as defined in previous studies, two thresholds (5–7 and 56.6–138.4 for NEWS2 and COVID-GRAM, respectively) could better identify patients with low, medium and high risk of progression to critical COVID-19 [1, 2]. Indeed, the same values described above were calculated for the optimal clinical thresholds defined in the literature.

Statistical analyses were performed using Prism Graphpad 8 software. A *p* value < 0.05 was considered significant.

Results

During the study period (as shown in Fig. 1), 152 patients were hospitalised for SARS-CoV-2 in Clinics of Infectious Diseases of Perugia and Terni. All the included patients were diagnosed with COVID-19 for the first time. Thirty-one were excluded due to insufficient data to calculate one or both scores at hospital admission. Therefore, 121 patients were included in the analysis. Among these, 50 (41.3%) patients presented critical illness. Analysing the subgroup of excluded patients, we found that 11/31 (35.5%) developed critical COVID-19, and among these, 6 patients died. Indeed, including these patients, the prevalence of severe COVID-19 would remain high (40.1%).

Fig. 1 Patient selection flow chart

The two scores were calculated using data obtained at hospital admission. This timing corresponds to a median of 8 days (interquartile range 5–11 days) after symptoms onset.

Baseline characteristics of patients are summarised in Table 1. The mean age was 64.5, standard deviation (SD) \pm 13.4 years; critical patients had a mean age slightly higher than non-critical patients (67.4, SD 10.7 years versus 62.5, SD 14.8 years, $p=0.04$). Percentage of male is

higher in critical patients compared to non-critical ones (78% and 56%, respectively, $p=0.01$).

Among the total cohort, 54.5% referred dyspnoea, and it was more observed in the critical group (72.0% versus 42.3% of non-critical patients, $p=0.001$).

We observed an increased neutrophil–lymphocyte ratio in total population (median 4.4, IQR 2.7–8.2) and it is

Table 1 Demographics, comorbidities and clinical presentation

	Total population	Critical illness	
		Yes	No
No. (%)	121	50 (41.3)	71 (58.7)
Age, mean (SD) [range], years	64.5 (13.4) [31–90]	67.4 (10.7) [48–89]	62.5 (14.8) [31–90]
Sex			
Male, no. (%)	79/121 (65.3)	39/50 (78.0)	40/71 (56.0)
Comorbidities, no. (%)			
0	59/121 (48.8)	23/50 (46.0)	36/71 (50.7)
1	39/121 (32.2)	15/50 (30.0)	24/71 (33.8)
2	14/121 (11.6)	8/50 (16.0)	6/71 (8.5)
3	8/121 (6.6)	4/50 (8.0)	4/71 (5.6)
4	1/121 (0.8)	0/50 (0)	1/71 (1.4)
5	0/121 (0)	0/50 (0)	0/71 (0)
Malignant disease, no. (%)	10/121 (8.3)	6/50 (12.0)	4/71 (5.6)
Hemoptysis, no. (%)	0/121 (0)	0/121 (0)	0/71 (0)
Dyspnoea, no. (%)	66/121 (54.5)	36/50 (72.0)	30/71 (42.3)
Unconsciousness, no. (%)	0/121 (0)	0/100 (0)	0/71 (0)
Neutrophil–lymphocyte ratio, median [IQR]	4.4 [2.7–8.2]	7.6 [4.1–12.1]	3.8 [2.1–5.3]
Lactate dehydrogenase, median [IQR], U/L	265.0 [190.0–373.0]	373.0 [271.0–516.5]	221.0 [166.0–283.0]
Direct bilirubin, median [IQR], μ mol/L	6.0 [4.0–8.0]	6.0 [4.5–8.5]	9.0 [1.0–9.0]
Radiological findings of lung damage, No. (%)	104/121 (86.0)	49/50 (98.0)	55/71 (77.5)
NEWS2, median [IQR]	4 [1–6]	6 [4–8]	2 [0–4]
COVID-GRAM, median [IQR]	128.5 [108.6–148.3]	137.0 [128.5–155.8]	117.2 [88.7–134.1]

NEWS national early warning score; SD standard deviation; IQR interquartile range

significantly higher in critical patients (median 7.6, IQR 4.1 versus median 3.8, IQR 2.1–5.3, $p < 0.0001$).

Lactate dehydrogenase was increased in the total population (median 265 U/L, IQR 190–373 U/L) and higher in patients with severe COVID-19 compared to non-severe disease (median 373.0 U/L, IQR 271.0–516.5 U/L versus 221.0 U/L, IQR 166.0–283.0 U/L, $p < 0.0001$).

NEWS and COVID-GRAM data had not a Gaussian distribution. For both the tools, Mann–Whitney U test confirmed the differences of scores between patients with severe and not severe COVID-19 ($p < 0.0001$).

The ROC curves of NEWS2 and the new COVID-GRAM for predicting critical illness are depicted in Fig. 2. The NEWS2 AUROC curve measured 0.87 (standard error, SE 0.03; 95% CI 0.80–0.93; $p < 0.0001$). The new specific COVID-GRAM AUROC curve measured 0.77 (SE 0.04; 95% CI 0.68–0.85; $p < 0.0001$). Hanley–McNeil test showed that NEWS2, better predicted severe COVID-19 ($Z = 2.03$).

According to the Youden index (J), the optimal thresholds were 4 and 123.2 for NEWS2 and COVID-19 score, respectively. As shown in Table 2, at the selected thresholds, sensitivity was 86 and 88 for NEWS2 and Liang’s COVID-GRAM, respectively. Specificity was higher for NEWS2 (70.4%) compared to COVID-GRAM (62%). NEWS2 at 4 had a positive likelihood ratio of 2.9 while for COVID-GRAM of 2.3. Similarly, positive predictive value was higher for NEWS2 (67.2%) respect to COVID-GRAM (62.9%). The negative likelihood ratios were 0.2 for both the




Fig. 2 Receiver-operating characteristic (ROC) curves for prediction of critical COVID-19 illness: ROC curve for critical COVID-19 illness using NEWS2 (■ dashed line) and COVID-GRAM (● continuous line) of COVID-19 patients at hospital admission. NEWS2 showed an area under the ROC curve (AUROC) curve of 0.87 (standard error, SE 0.03; 95% CI 0.80–0.93; $p < 0.0001$). The COVID-GRAM AUROC curve measured 0.77 (SE 0.04; 95% CI 0.68–0.85; $p < 0.0001$)

Table 2 Prognostic accuracy of NEWS2 and Liang’s COVID-19 score for severe COVID-19 using the optimal threshold values individuated by Youden index ($N = 121$)

(95% CI)	NEWS2 ≥ 4	COVID-GRAM (Liang) ≥ 123.2
Sensitivity, %	86.0 (73.3–94.2)	88.0 (76.2–94.4)
Specificity, %	70.4 (58.4–80.7)	62.0 (50.3–72.4)
Positive likelihood ratio	2.9 (2.0–4.2)	2.3 (1.7–3.2)
Negative likelihood ratio	0.2 (0.1–0.4)	0.2 (0.1–0.4)
Positive predictive value, %	67.2 (58.4–74.9)	62.9 (55.1–70.0)
Negative predictive value, %	87.7 (78.0–93.5)	88.2 (77.6–94.2)
Accuracy, %	76.9 (68.3–84.0)	72.7 (63.9–80.4)

NEWS national early warning score; COVID-19 Coronavirus Disease 19; CI confidence interval

scores. Similar negative predictive value was found for the scores (87.7% and 88.2% for NEWS2 and COVID-GRAM, respectively). Accuracy was 76.9 and 72.7 for NEWS2 and Liang’s score, respectively.

Data of sensitivity, specificity, positive and negative likelihood ratio, positive and negative predictive values and accuracy of optimal clinical thresholds are shown in Supplementary Table 1.

Discussion

Liang et al. generated a specific COVID-19 score based on characteristics of patients of a nationwide Chinese cohort. Before this study, other authors underlined the importance of an early severity of illness assessment. For example, Bradley et al. [9] in a cohort of 830 patients, compared rapid scores as CURB-65, NEWS2 and qSOFA and observed that $\text{NEWS2} \geq 5$ had a negative predictive value of 98.0% for early mortality. However, they underlined the necessity of a COVID-19 score that focus on respiratory failure rather than circulatory collapse.

In a previous study, we demonstrated that, in COVID-19 patients, NEWS2 is useful to quickly identify patients at risk of rapid deterioration and to predict ICU admission. Furthermore, according to this study, the use of the score could be implemented basing on two different thresholds: 5 and 7 [2]. Furthermore, another study performed analysing an UK cohort of 296 patients supported the use of NEWS2 to identify deterioration of hospitalised COVID-19 patients [10].

In this study, through the Youden Index, we individuated for simplicity a threshold with a good balance of sensitivity and specificity. It was calculated to compare NEWS2 and COVID-GRAM, but it does not represent the best clinical threshold. In clinical practice, two thresholds (5–7 and 56.6–138.4 for NEWS2 and COVID-GRAM, respectively) could better fit the necessity of rapid individuation

of patients at risk of deterioration and exclusion of clinically stable patients. Indeed, for both scores, the lower threshold could better individuate patients with low risk of critical progression with a sensitivity of 100% and 86.0% for COVID-GRAM and NEWS2, respectively. At the same time, the higher threshold better predicted the risk of critical course (specificity of 78.9% and 98.6% for COVID-GRAM and NEWS2, respectively) (Supplementary Table 1).

However, 79 patients had a COVID-GRAM score between the two thresholds, with a medium risk of progression; among these, 31.6% had a severe COVID-19. Concerning NEWS2, only 25 patients had a score between the two thresholds and, among these, 52.0% developed severe COVID-19 (data not shown).

We observed that NEWS2 applied for identification of patients with a high risk of deterioration in different clinical setting [5] could identify patients at risk of severe COVID-19 better than the COVID specific Liang's Score. Of note, although COVID-19 is a disease involving mainly the lungs, among the ten variables required by COVID-GRAM, respiratory rate, oxygen saturation, and supplemental oxygen are not considered differently from NEWS2.

Multiple factors need to be discussed. First, the two cohorts of patients are different: the mean age of our patients is higher than in Liang ones (49 versus 65 years). Interestingly, in our cohort, age is similar in critical and non-critical patients. In Liang's cohort, the mean age was higher in critical than in non-critical patients. Moreover, 51.2% of our patients have at least one coexisting condition, as opposed to 25.1% in Liang's cohort; a higher percentage of our patients, comparing to the Chinese cohort, developed a severe disease (41.3% versus 8.2%) and had abnormal chest radiological findings (86.0% versus 71.0%).

Unfortunately, with published data, we are not able to evaluate NEWS2 in Liang's cohort. The main strengths of this study are the homogeneity of the cohort and the setting as a double-centre study. The NEWS2 is a more practical tool that have been largely validated in other clinical setting for identification of patients with a high risk of deterioration and shows a good applicability to identify the critical COVID-19. The main limitations of our study are the retrospective study design and the small number of patients.

In conclusion, both scores provide useful information to manage patients with COVID-19, but NEWS2 seemed to be simpler and to better predict than COVID-GRAM the progression to critical COVID-19.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s15010-021-01620-x>.

Acknowledgements None.

Author contributions Study conception and design: GVDS, AG, and DF. Material preparation, and data analysis: A G. Data collection: AG

and FS. The first draft of the manuscript was written by AG and revised by GVDS and DF, and all the authors commented on the manuscript. All the authors read and approved the final manuscript.

Funding Open access funding provided by Università degli Studi di Perugia within the CRUI-CARE Agreement. This research did not receive any specific grant from funding agencies in the public commercial, or not-for-profit sectors.

Availability of data and materials Available on reasonable request.

Declarations

Conflict of interest Nothing to declare.

Ethical approval The study was approved by the Ethics Committee of the Umbria Region (protocol number 18344/20/OV).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. *JAMA Intern Med.* 2020;180:1081–9.
2. Gidari A, De Socio GV, Sabbatini S, Francisci D. Predictive value of national early warning score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infect Dis.* 2020;52:698.
3. Royal College of Physicians. National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Updated report a work party. 2017. <https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2>
4. World Health Organization. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Geneva: WHO; 2020. <https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>
5. Fernando SM, Fox-Robichaud AE, Rochweg B, Cardinal P, Seely AJE, Perry JJ, et al. Prognostic accuracy of the Hamilton early warning score (HEWS) and the national early warning score 2 (NEWS2) among hospitalized patients assessed by a rapid response team. *Crit Care.* 2019;23:60.
6. Pimentel MAF, Redfern OC, Gerry S, Collins GS, Malycha J, Prytherch D, et al. A comparison of the ability of the national early warning score and the national early warning score 2 to identify patients at risk of in-hospital mortality: a multi-centre database study. *Resuscitation.* 2019;134:147–56.
7. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology.* 1982;143:29–36.

8. Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;3:32–5.
9. Bradley P, Frost F, Tharmaratnam K, Wootton DG. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. *BMJ Open Respir Res*. 2020;7:e000729.
10. Baker KF, Hanrath AT, van der Loeff SI, Kay LJ, Back J, Duncan CJ. National early warning score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. *Clin Med*. 2021;21:84.